Laura Wood, RN, MSN, OCN

Experts discuss optimizing renal cell carcinoma (RCC) treatment by integrating patient-reported outcomes and clinician insights.

Experts discuss patient-reported outcomes from the TiNivo-2 trial, focusing on quality of life and the treatment experience.

Experts discuss survival data from the TiNivo-2 phase 3 trial and practical approaches to dose management in clinical practice.

Experts discuss optimizing VEGFR-tyrosine kinase inhibitor (TKI) therapy, focusing on patient selection and management strategies in the clinical setting.

Experts discuss the efficacy profile of tivozanib monotherapy and clinical management strategies in advanced renal cell carcinoma (RCC).

Experts discuss the rational treatment selection of the VEGFR-tyrosine kinase inhibitor (TKI) tivozanib following progression after immune checkpoint inhibitor (ICI) therapy.

Experts discuss sequencing strategies in renal cell carcinoma (RCC), focusing on optimizing treatment selection after immune-oncology (IO)–based therapy.

Experts discuss first-line treatment strategies for renal cell carcinoma (RCC) in 2025, navigating the evolving therapeutic landscape.

Laura Wood discusses the successful integration of avelumab, erdafitinib, and enfortumab vedotin-ejfv into oncology nursing practice.

Laura Wood on collaboration between departments when treating patients with cancer who are receiving immunotherapy treatments.

Laura Wood explains the education opportunities available to nurses in the field of immunotherapy.